IP Library › Granted Patent US 11,352,342
Granted Patent B2
US 11,352,342 · App. 16/999,806 · Granted Jun 7, 2022

Pharmaceutical compounds

Inventors: Giles Albert Brown (Cambridge, GB); Julie Elaine Cansfield (Cambridge, GB); Miles Stuart Congreve (Cambridge, GB); Benjamin Gerald Tehan (Cambridge, GB); Barry John Teobald (Cambridge, GB)
Assignee: Heptares Therapeutics Limited
C07D403/04A61P25/02A61P25/18A61P25/28C07D401/08C07D401/14C07D403/14C07D413/14C07D417/14C07D451/02C07D451/14C07D491/107C07D498/08
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,352,342
App. No.
16/999,806
Granted
Jun 7, 2022
Kind
B2
Abstract

This invention relates to compounds that are agonists of the muscarinic M 1 and/or M 4 receptor and which are useful in the treatment of diseases mediated by the muscarinic M 1 and M 4 receptors. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formula (1) wherein X 1 ; X 2 ; R 1 and R 4 are as defined herein.

Claims (33)

1. A compound of formula (4):

or a salt thereof, wherein:

R 1 is CONR 5 R 6 ;

R 4 is H or a C 1-6 non-aromatic hydrocarbon group which is optionally substituted with one to six fluorine atoms; and

R 5 and R 6 are independently selected from hydrogen and a non-aromatic C 1-6 hydrocarbon group optionally substituted with one or more fluorine atoms or R 5 and R 6 are joined together to form a monocyclic or bicyclic ring.

2. The compound according to claim 1 , or a salt thereof, wherein R 1 is selected from the group consisting of:

3. The compound according to claim 1 , or a salt thereof, wherein R 1 is:

4. The compound according to claim 1 , or a salt thereof, wherein R 4 is H or methyl.

5. The compound according to claim 1 , or a salt thereof, wherein R 4 is H.

6. The compound according to claim 1 which is selected from the group consisting of:

ethyl 2-{(1R,5S,6r)-6-[(2-methylpropyl)carbamoyl]-3-azabicyclo[3.1.0]hex-3-yl}-6-azaspiro[3.4]octane-6-carboxylate;

ethyl 2-{(1R,5S,6r)-6-[(cyclobutylmethyl)carbamoyl]-3-azabicyclo[3.1.0]hex-3-yl}-6-azaspiro[3.4]octane-6-carboxylate;

ethyl 2-{(1R,5S,6r)-6-[(1-methylcyclobutyl)carbamoyl]-3-azabicyclo[3.1.0]hex-3-yl}-6-azaspiro[3.4]octane-6-carboxylate;

ethyl 2-{(1R,5S,6r)-6-[ethyl(methyl)carbamoyl]-3-azabicyclo[3.1.0]hex-3-yl}-6-azaspiro[3.4]octane-6-carboxylate;

ethyl 2-[(1R,5S,6r)-6-(diethylcarbamoyl)-3-azabicyclo[3.1.0]hex-3-yl]-6-azaspiro[3.4]octane-6-carboxylate;

methyl 2-[(1R,5S,6r)-6-(diethylcarbamoyl)-3-azabicyclo[3.1.0]hex-3-yl]-6-azaspiro[3.4]octane-6-carboxylate;

ethyl 2-{(1R,5S,6r)-6-[methyl(propan-2-yl)carbamoyl]-3-azabicyclo[3.1.0]hex-3-yl}-6-azaspiro[3.4]octane-6-carboxylate;

ethyl 2-{(1R,5S,6r)-6-[ethyl(propan-2-yl)carbamoyl]-3-azabicyclo[3.1.0]hex-3-yl}-6-azaspiro[3.4]octane-6-carboxylate;

methyl 2-{(1R,5S,6r)-6-[ethyl(propan-2-yl)carbamoyl]-3-azabicyclo[3.1.0]hex-3-yl}-6-azaspiro[3.4]octane-6-carboxylate;

ethyl 2-{(1R,5S,6r)-6-[cyclopropyl(ethyl)carbamoyl]-3-azabicyclo[3.1.0]hex-3-yl}-6-azaspiro[3.4]octane-6-carboxylate;

ethyl 2-[(1R,5S,6r)-6-(pyrrolidin-1-ylcarbonyl)-3-azabicyclo[3.1.0]hex-3-yl]-6-azaspiro[3.4]octane-6-carboxylate;

ethyl 2-[(1R,5S,6r)-6-(piperidin-1-ylcarbonyl)-3-azabicyclo[3.1.0]hex-3-yl]-6-azaspiro[3.4]octane-6-carboxylate;

ethyl 2-[(1R,5S,6r)-6-(azepan-1-ylcarbonyl)-3-azabicyclo[3.1.0]hex-3-yl]-6-azaspiro[3.4]octane-6-carboxylate;

ethyl 2-[(1R,5S,6r)-6-(2-azaspiro[3.3]hept-2-ylcarbonyl)-3-azabicyclo[3.1.0]hex-3-yl]-6-azaspiro[3.4]octane-6-carboxylate;

ethyl 2-[(1R,5S,6r)-6-(4-azaspiro[2.3]hex-4-ylcarbonyl)-3-azabicyclo[3.1.0]hex-3-yl]-6-azaspiro[3.4]octane-6-carboxylate;

ethyl 2-[(1R,5S,6r)-6-(1-azaspiro[3.3]hept-1-ylcarbonyl)-3-azabicyclo[3.1.0]hex-3-yl]-6-azaspiro [3.4]octane-6-carboxylate;

methyl 2-[(1R,5S,6r)-6-(1-azaspiro [3.3]hept-1-ylcarbonyl)-3-azabicyclo [3.1.0]hex-3-yl]-6-azaspiro[3.4]octane-6-carboxylate; and

ethyl 2-[(1R,5S,6r)-6-(6-oxa-1-azaspiro[3.3]hept-1-ylcarbonyl)-3-azabicyclo[3.1.0]hex-3-yl]-6-azaspiro[3.4]octane-6-carboxylate;

or a salt thereof.

7. A method of treating Alzheimer's disease, dementia with Lewy bodies or schizophrenia in a subject, comprising administering to the subject an effective amount of a compound according to claim 1 , or a salt thereof.

8. A method of treating Alzheimer's disease in a subject, comprising administering to the subject an effective amount of a compound according to claim 1 , or a salt thereof.

9. A method of treating dementia with Lewy bodies in a subject, comprising administering to the subject an effective amount of a compound according to claim 1 , or a salt thereof.

10. A method of treating schizophrenia in a subject, comprising administering to the subject an effective amount of a compound according to claim 1 , or a salt thereof.

Assignments (2)
CHANGE OF NAME Recorded Sep 9, 2024
From: HEPTARES THERAPEUTICS LIMITED
To: NXERA PHARMA UK LIMITED
Reel/Frame 068524/0400 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 17, 2020
From: BROWN, GILES ALBERT; CANSFIELD, JULIE ELAINE; CONGREVE, MILES STUART; TEHAN, BENJAMIN GERALD; TEOBALD, BARRY JOHN
To: HEPTARES THERAPEUTICS LIMITED
Reel/Frame 053798/0780 →
Priority Claims (1)
GB 1709652 · Jun 16, 2017 · national
Continuity (3)
Continuation 16411821 · May 14, 2019
Division 16010831 · Jun 18, 2018
Related Publication 20210040067A1 · Feb 11, 2021
Cited By (3)
US 12,202,843 US 12,215,099 US 12,291,512